EXAS Stock Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Exact Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$48.43|
|52 Week High||US$133.99|
|52 Week Low||US$46.15|
|1 Month Change||-22.69%|
|3 Month Change||-35.91%|
|1 Year Change||-55.58%|
|3 Year Change||-50.44%|
|5 Year Change||32.79%|
|Change since IPO||228.34%|
Recent News & Updates
Exact Sciences Won't Likely Escape Consolidation In The Industry
The current tight macro environment is conducive to consolidation in Biotech. Exact Sciences needs to turn cash flow positive to avoid liquidity problems. M&A might be a solution to scale and reduce cash burn, but it doesn't come without problems.
Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
Exact Sciences continues to record strong growth and is expected to report growth for the foreseeable future. Regardless of the steady revenue growth, the EXAS stock is under a lot of selling pressure as the overall market continues its downward trajectory. I believe the relentless selling will provide a great opportunity to grab EXAS at a reasonable valuation for its growth prospects. Guardant Health's colorectal cancer test might have an impact on Cologuard’s growth in the coming quarters. Therefore, I am not looking to make EXAS a major component of the Compounding Healthcare "Bio Boom" Portfolio at this time. I take a look at the company's current valuation to help form my plan of attack for EXAS as the market continues to experience elevated selling pressure.
|EXAS||US Biotechs||US Market|
Return vs Industry: EXAS underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: EXAS underperformed the US Market which returned -12.3% over the past year.
|EXAS Average Weekly Movement||10.0%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: EXAS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: EXAS's weekly volatility (10%) has been stable over the past year.
About the Company
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.
Exact Sciences Fundamentals Summary
|EXAS fundamental statistics|
Is EXAS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXAS income statement (TTM)|
|Cost of Revenue||US$483.47m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.24|
|Net Profit Margin||-40.26%|
How did EXAS perform over the long term?See historical performance and comparison
Is Exact Sciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXAS ($47.89) is trading below our estimate of fair value ($125.45)
Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXAS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: EXAS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXAS is overvalued based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.5x).
How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXAS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXAS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXAS's revenue (14.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: EXAS's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAS is forecast to be unprofitable in 3 years.
How has Exact Sciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXAS is currently unprofitable.
Growing Profit Margin: EXAS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-22.88%), as it is currently unprofitable.
How is Exact Sciences's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.2B) exceed its short term liabilities ($481.0M).
Long Term Liabilities: EXAS's short term assets ($1.2B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: EXAS's net debt to equity ratio (41.9%) is considered high.
Reducing Debt: EXAS's debt to equity ratio has increased from 2% to 67% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EXAS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EXAS has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 1.3% each year.
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EXAS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Conroy (55 yo)
Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD14.63M) is above average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Experienced Management: EXAS's management team is considered experienced (3.4 years average tenure).
Experienced Board: EXAS's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.
Exact Sciences Corporation's employee growth, exchange listings and data sources
- Name: Exact Sciences Corporation
- Ticker: EXAS
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$8.426b
- Shares outstanding: 175.95m
- Website: https://www.exactsciences.com
Number of Employees
- Exact Sciences Corporation
- 5505 Endeavor Lane
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.